Repository logo

Browsing by Author "Guerrero, A."

Now showing 1 - 1 of 1
  • New findings in HCV genotype distribution in selected West European, Russian and Israeli regions
    Publication . Kartashev, Vladimir; Döring, Matthias; Nieto, Leonardo; Coletta, Eleda; Kaiser, Rolf; Sierra, Saleta; HCV EuResist Study group; Guerrero, A.; Stoiber, H.; Paar, C.; Vandamme, A. M.; Nevens, F.; Ranst, M. Van; Cuypers, L.; Braun, P.; Ehret, R.; Obermeier, M.; Schneeweiss, S.; Scholten, S.; Römer, K.; Isernhagen, K.; Qurashi, N.; Heger, E.; Knops, E.; Neumann-Fraune, M.; Timm, J.; Walker, A.; Lübke, N.; Wedemeyer, H.; Wiesch, J. Schulze zur; Lütgehetmann, M.; Polywka, S.; Däumer, M.; Hoffmann, D.; Protzer, U.; Marascio, N.; Foca, A.; Liberto, M. C.; Barreca, G. S.; Galati, L.; Torti, C.; Pisani, V.; Perno, C. F.; Ceccherini-Silberstein, F.; Cento, V.; Ciotti, M.; Zazzi, M.; Rossetti, A.; De Luca, A.; Caudai, C.; Mor, O.; Devaux, C.; Staub, T.; Araujo, F.; Gomes, P.; Cabanas, J.; Markin, N.; Khomenko, I.; Govorukhina, M.; Lugovskaya, G.; Dontsov, D.; Mas, A.; Martró, E.; Saludes, V.; Rodríguez-Frías, F.; García, F.; Casas, P.; Iglesia, A. de la; Alados, J. C.; Pena-López, M. J.; Rodríguez, M. J.; Galán, J. C.; Suárez, A.; Cardeñoso, L.; Guerrero, M. D.; Vegas-Dominguez, C.; Blas-Espada, J.; García, R.; García-Bujalance, S.; Benítez-Gutiérrez, L.; Mendoza, C. de; Montiel, N.; Santos, J.; Viciana, I.; Delgado, A.; Martínez-Sanchez, P. A.; Fernández-Alonso, M.; Reina, G.; Trigo, M.; Echeverría, M. J.; Aguilera, A.; Navarro, D.; Bernal, S.; Lozano, M. C.; Fernández-Cuenca, F.; Orduña, A.; Eiros, J. M.; Ortíz de Lejarazu, R.; Martínez-Sapiña, A. M.; García-Díaz, A.; Haque, T.
    BACKGROUND: HCV affects 185 million people worldwide and leads to death and morbidities. HCV has a high genetic diversity and is classified into seven genotypes and 67 subtypes. Novel anti-HCV drugs (Direct-Acting-Antivirals) eligibility, resistance and cure rates depend on HCV geno/subtype (GT). OBJECTIVES: Analysis of epidemiological information and viral GT from patients undergoing viral genotyping in 2011-2015. STUDY DESIGN: Anonymized information from 52 centers was analyzed retrospectively. RESULTS: 37,839 samples were included in the study. We show that the GT distribution is similar throughout Western European countries, with some local differences. Here GTs 1 and 2 prevalences are lower and of GT4 higher than in all previous reports. Israel has a unique GT pattern and in South Russia the GT proportions are more similar to Asia. GTs 5 and 6 were detected in very low proportions. Three cases of the recombinant genotype P were reported in Munich (Germany). In addition, we observed that GT proportion was dependant on patientś gender, age and transmission route: GTs 1b and 2 were significantly more common in female, older, nosocomially-infected patients, while GTs 1a, 3 and 4 were more frequent in male, younger patients infected by tattooing, drug consume, and/or sexual practices. In infections acquired by drug consume, GTs 1a (35.0%) and 3 (28.1%) prevailed. In infections related to sexual practices lower proportion of GT3 (14.0%) and higher of GT4 (20.2%) were detected. GT4 was mostly abundant in MSM (29.6%). HIV coinfection was significantly associated with higher proportions GTs 1a and 4 (42.5% and 19.3%, respectively). CONCLUSION: Genotype prevalence evolves and correlates to epidemiological factors. Continuous surveillance is necessary to better assess hepatitis C infection in Europe and to take appropriate actions
    2016-08Journal article Open access Show more